Iva Toudjarska joined Xontogeny in January 2021 as Vice President of Portfolio Operations. Iva’s responsibilities include portfolio company oversight, program development and driving strategic efficiencies.
Iva has 20 years of demonstrated success in delivering scientific program excellence through integration of scientific, business and commercial insights and ability to execute on internal and partner strategy. With strong scientific background across wide range of therapeutic areas and platforms, Iva has contributed to the development of multiple therapeutics and platform trough her consulting and in-house engagements with top Biotech and Pharma companies.
Prior to joining Xontogeny, Iva was an SVP at Evotec responsible for BRIDGEs Partnerships North America and NewCos where she spearheaded building and operations of strategic academic partnerships. Prior to this, Iva spent 6 years in Biopharma strategy consulting. As part of Putnam Associates, she led teams in crafting comprehensive product and portfolio positioning and prioritization strategies for drug development in US and international markets. As Principal at Halloran Consulting Group, Iva led strategy business area with early stage biopharma clients informing pre-clinical, clinical and regulatory strategy for therapeutics and platforms and partnered with investment clients to inform due diligence and support buy-side and sell-side transactions in wide variety of indications. Previously, she was a founding employee at Alnylam Pharmaceuticals, the leader in RNAi therapeutics. During her 9-year tenure at Alnylam, as part of a multi-disciplinary team she advanced several programs to clinic.
Iva earned a PhD from Bulgarian Academy of Sciences in Molecular Genetics and MBA from F.W. Olin Graduate School of Business at Babson College.